In the LabSecond patient dies in Zafgen obesity drug trial By Robert Weisman — Boston GlobeDec. 2, 2015 Reprints Zafgen CEO Thomas Hughes works in his office. Lane Turner/The Boston Globe Second patient dies in Zafgen obesity drug trial About the Author Reprints Robert Weisman — Boston Globe [email protected] @GlobeRobW Tags biotech clinical trials obesity
Pharmalot Ed Silverman STAT Plus: Drug companies and pharmacies reach $17.3 billion settlement over opioid crisis
Biotech Adam Feuerstein and Damian Garde STAT Plus: FDA panel unanimously endorses Eisai’s Alzheimer’s drug
Biotech Adam Feuerstein STAT Plus: Novocure’s electric fields device prolongs survival in lung cancer, but doubts remain
Exclusive Brittany Trang STAT Plus: Hospitals want to buy doctors’ happiness with Nuance’s AI scribe. What they’re paying varies